Biointron’s Q1 2026 Antibody Industry Trends report aims to explore the events and trends of the biopharmaceutical industry in January, February, and March. This quarter, three novel monoclonal antibody drugs have been approved by China.
A global resurgence of measles has been driven by declining vaccination coverage and gaps in herd immunity, renewing interest in antibody-based therapeutic strategies targeting measles virus (MeV). Recent studies demonstrate rapid advances in the identification, structural characterization, and functional evaluation of monoclonal antibodies (mAbs) directed against key viral glycoproteins.
Conditionally activatable antibodies are an emerging class of engineered biologics designed to improve the therapeutic index. The therapeutic index can be defined as the balance between efficacy and toxicity, by restricting antibody activity to disease sites.
Time: April 15 - 19, 2026
Location: Boston, MA
Booth: #1228
Time: April 28 – 30, 2026
Location: Seoul, South Korea
Booth: #B31
Time: May 9 - 10, 2026
Location: Boston, MA
This webinar provides an overview of Antibody-Drug Conjugates (ADCs) and expanded drug conjugates (XDCs), with a focus on Biointron's experiences and capabilities.
Watch our webinar on accelerating antibody discoveru. Single B cell sorting-based antibody screening can help identify a population of diverse and functional hits with a shortened timeline. Integrated with our high-throughput expression, validation and developability assay platforms, the path from hits to candidate can be more faster and more efficient with data beyond binding alone.
During the NextGen Biomed 2026 conference in London, Lei Shi, PhD, Senior Vice President of Biointron, discussed Biointron's unique single B cell sorting-based antibody discovery process integrated with our high-throughput expression, validation and developability platforms.
When you’re a small biotech with big ambitions, every week counts. For Macomics Limited, that meant finding a way to get high-quality antibodies quick···
The demand for fully human therapeutic antibodies continues to grow, driving the need for more efficient discovery platforms.
Case 1: Tag-Free Vaccine Protein. During the generation of stable cell lines, cells are selected and screened to identify clones that stably express t···
Apply for Biointron's Quarterly Travel Grant. Receive $800 to support early-career antibody researchers in attending scientific conferences, symposia, and workshops.
Submit a quick Biointron testimonial and we’ll send you a $25 Amazon gift card. Simple, fast, and appreciated!
Join Biointron’s Google Review & Reward Program! Share your experience on Biointron google profile and earn a $25 gift card as reward!
Spotlight on Antibodies is a podcast from Biointron, where we bring you the latest antibody industry trends. This month in April, we'll highlight ATP-dependent switch antibodies, the throughput-quality gap in antibody discovery, and multiple myeloma antibody treatments.
Spotlight on Antibodies is a podcast from Biointron, where we bring you the latest antibody industry trends. This month in March, we'll highlight antibody allostery, trends in developability, and anti-IgE therapeutics.
Spotlight on Antibodies is a podcast from Biointron, where we bring you the latest antibody industry trends. This month in February, we'll highlight radioantibodies, antibody-cytokine fusion proteins, and conditionally active antibodies.
VHH half extension mechanisms like Fc fusion, albumin binding, and PEGylation to improve pharmacokinetics and performance. Contact Biointron.
Learn how multivalent and bispecific VHH antibodies are engineered, their advantages, applications, and key challenges in therapeutic development.
April 2026 activity saw consolidation in the ADC space, continued expansion of next-generation antibody formats (including DACs and trispecifics), and strong financing for platform-driven oncology innovation. Strategic M&A and high-value partnerships highlighted sustained interest in complex biologics and targeted delivery technologies.
You can also contact us on the Scientist and Science Exchange marketplaces.
